• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.

作者信息

Ghielmini Michele

机构信息

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.

出版信息

Cancer Treat Rev. 2005 Dec;31(8):644-7. doi: 10.1016/j.ctrv.2005.09.010. Epub 2005 Nov 10.

DOI:10.1016/j.ctrv.2005.09.010
PMID:16289339
Abstract
摘要

相似文献

1
Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.对于未经治疗的III/IV期滤泡性淋巴瘤患者，在环磷酰胺、长春新碱和泼尼松的基础上加用利妥昔单抗可延长至治疗失败或病情进展的时间。
Cancer Treat Rev. 2005 Dec;31(8):644-7. doi: 10.1016/j.ctrv.2005.09.010. Epub 2005 Nov 10.
2
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.氟达拉滨联合米托蒽醌加或不加利妥昔单抗与CHOP加或不加利妥昔单抗作为滤泡性淋巴瘤患者的一线治疗方案比较
J Clin Oncol. 2004 Jul 1;22(13):2654-61. doi: 10.1200/JCO.2004.07.170. Epub 2004 May 24.
3
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.R-CVP与单纯环磷酰胺、长春新碱和泼尼松相比，用于既往未治疗的晚期滤泡性淋巴瘤患者的III期研究。
J Clin Oncol. 2008 Oct 1;26(28):4579-86. doi: 10.1200/JCO.2007.13.5376. Epub 2008 Jul 28.
4
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.高肿瘤相关巨噬细胞含量预示着接受利妥昔单抗和环磷酰胺-阿霉素-长春新碱-泼尼松治疗的滤泡性淋巴瘤患者预后良好。
Clin Cancer Res. 2007 Oct 1;13(19):5784-9. doi: 10.1158/1078-0432.CCR-07-0778.
5
CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.在滤泡性淋巴瘤患者中，采用CHOP化疗后行利妥昔单抗巩固治疗作为一线治疗方案。一项2期试验的长期随访。
Eur J Haematol. 2007 May;78(5):453-5. doi: 10.1111/j.1600-0609.2007.00848.x. Epub 2007 Apr 5.
6
[Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].[滤泡性淋巴瘤和套细胞淋巴瘤治疗策略的最新进展]
Rinsho Ketsueki. 2006 Jun;47(6):495-512.
7
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.含蒽环类药物和氟达拉滨的方案联合或不联合利妥昔单抗用于治疗晚期滤泡性淋巴瘤患者。
Cancer. 2009 May 1;115(9):1906-13. doi: 10.1002/cncr.24222.
8
Clinical and molecular complete remission of primary duodenal follicular lymphoma following treatment with rituximab and cyclophosphamide, vincristine and prednisone chemotherapy.利妥昔单抗联合环磷酰胺、长春新碱和泼尼松化疗后原发性十二指肠滤泡性淋巴瘤的临床及分子完全缓解
Intern Med J. 2009 Oct;39(10):706-7. doi: 10.1111/j.1445-5994.2009.02027.x.
9
Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.嵌合抗CD20单克隆抗体（美罗华）用于复发滤泡性非霍奇金淋巴瘤的缓解诱导及维持治疗：一项III期随机临床试验——组间协作研究
Ann Hematol. 2002 Oct;81(10):553-7. doi: 10.1007/s00277-002-0548-2. Epub 2002 Oct 17.
10
The therapeutic use of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的治疗应用。
Eur J Haematol Suppl. 2007 Jan(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.